overt diabetes

Overview

Overt diabetes refers to clinically manifest diabetes mellitus, typically distinguished from milder dysglycemia or gestational hyperglycemia by meeting diagnostic thresholds for diabetes at the time of detection. In obstetric and endocrine contexts, the term is often used to describe diabetes that is already present or clearly established early in pregnancy, rather than hyperglycemia first recognized later in gestation. As a disease state, overt diabetes is associated with chronic hyperglycemia, insulin deficiency and/or insulin resistance, and a broad range of microvascular and macrovascular complications.

Biologically, overt diabetes is relevant because sustained elevation of blood glucose affects multiple organ systems, including the retina, kidney, heart, skeletal muscle, nervous system, and skin. It also influences infection risk, wound healing, and pregnancy outcomes. Recent research contexts linked to overt diabetes emphasize its role as a clinically important target for early detection, complication prevention, and risk stratification.

Focus of Latest Publications

Recent studies have characterized the substantial clinical burden and evolving management landscape of overt diabetes. In peritoneal dialysis patients, overt diabetes mellitus confers cardiovascular and mortality risks comparable to those observed in impaired fasting glucose, with underlying mechanisms mediated by β-cell dysfunction and insulin resistance. Emerging evidence has identified overt diabetes as a modifiable host-state factor influencing therapeutic outcomes in other disease contexts; a metabolic immunotherapy-readiness framework has been proposed integrating glycaemic control and endocrine monitoring to optimize treatment efficacy in patients undergoing chemo-immunotherapy.

Contemporary management strategies emphasize technology-enabled and educational approaches. Real-world evidence from European populations demonstrates that continuous glucose monitoring systems and automated insulin delivery platforms reduce daily management burden when adopted across age groups, though uptake and clinical outcomes vary. Digital educational interventions and complementary therapy approaches have been evaluated to enhance patient health literacy and empowerment. In elderly patients with overt diabetes, exercise training has been investigated for its effects on bone health and Age-related osteogenic failure.

Emerging therapeutic research focuses on targeted and immunomodulatory approaches. Nanoscale drug delivery systems—including nanoparticles, liposomes, and exosomes such as extracellular exosomes—are being investigated as carriers to enable targeted therapy and controlled drug release. These platforms aim to modulate the proinflammatory cytokine production and impaired T-lymphocyte tolerance implicated in diabetes pathogenesis, while enhancing drug bioavailability and reducing off-target systemic adverse effects.

The epidemiology of overt diabetes reveals shifting risk patterns and increasing prevalence in younger populations. Prospective cohort studies have documented incident diabetes following SARS-CoV-2 infection in large population samples, identifying viral infection as a previously underrecognized risk pathway. Concurrently, early-onset type 2 diabetes demonstrates increasing prevalence across diverse geographic regions, with sex-stratified analyses revealing population-specific risk determinants and trends.

Key Publications

• NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42402705)
• NEWJun Advances in Nano-Drug Delivery Systems for Chronic Autoimmune Diseases: A Focus on Diabetes Mellitus, Inflammatory Bowel Disease, and Rheumatoid Arthritis. (Molecules (Basel, Switzerland), 2026, PMID 42357492): "This review summarizes recent advances in nano-delivery technologies for three representative chronic autoimmune diseases: diabetes mellitus (DM), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA)."
• NEWJun Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy. (Breast cancer research and treatment, 2026, PMID 42360520): "We highlight diabetes as a potentially modifiable host-state factor influencing pathologic complete response."
• NEWJun Association of SARS-CoV-2 infection with incident diabetes among U.S. Veterans in a prospective longitudinal cohort. (PloS one, 2026, PMID 42361118): "To assess care-seeking patterns and incident diabetes risk following SARS-CoV-2 infection in a prospective longitudinal cohort."
• NEWJul Empowering Patients Through Literacy: A Randomized Controlled Trial of an Educational App for Evaluating Complementary Therapies in Diabetes Management. (Nursing open, 2026, PMID 42361247): "This study evaluated the effectiveness of an Educational App for Complementary Therapy in Diabetes Management in improving health literacy, quality of life, and diabetes empowerment through complementary therapy."
• Jul Prevalence, trends, and determinants of early-onset type 2 diabetes in northwest China: a sex-stratified analysis of ∼10 million community-dwelling population. (Diabetes research and clinical practice, 2026, PMID 42144064): "To investigate the trends and sex-specific risk factors of early-onset type 2 diabetes in northwest China."
• Jul Diabetes Technology Across the Lifespan of People With Diabetes (Ages 2-88 Years): Insights From the dt-Report on Usage Trends Across all Age Groups. (Journal of diabetes science and technology, 2026, PMID 42100882): "This analysis examines how uptake, clinical outcomes, and user experience vary across age groups in people with type 1 or type 2 diabetes."
• Jul Effects of exercise training on bone health in elderly people with type 2 diabetes without osteoporosis: A randomised clinical trial. (Diabetes research and clinical practice, 2026, PMID 42103115): "To assess the effects of exercise on non-invasive measures of bone health in elderly individuals with type 2 diabetes without osteoporosis."
• Apr The dt-Report: A Novel Real-World Data Approach to Understanding the Use and Impact of Diabetes Technology in European Countries. (Journal of diabetes science and technology, 2026, PMID 41933491): "technology use in people living with type 2 diabetes"
• Jun Concomitant Diabetes Mellitus Diminishes the Efficacy of Left Atrial Additional Ablation Following Pulmonary Vein Isolation　- A Subanalysis of the EARNEST-PVI Trial. (Circulation journal : official journal of the Japanese Circulation Society, 2026, PMID 41656093): "The aim of this study was to evaluate the efficacy of left atrial additional ablation after PVI in patients with and without DM."